Impending	O
Atypical	B:C4268744
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	O
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Impending	O
Atypical	O
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	B:C0238462
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Impending	O
Atypical	O
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	O
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	B:C0521324
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Impending	O
Atypical	O
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	O
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	O
Metastasis	B:C4255448
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	O
.	O

Impending	O
Atypical	O
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	O
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	B:C2267018
and	O
Denosumab	O
.	O

Impending	O
Atypical	O
Femoral	I:C4268744
Fracture	I:C4268744
in	O
Patients	O
With	O
Medullary	O
Thyroid	I:C0238462
Cancer	I:C0238462
With	O
Skeletal	O
Metastasis	O
Treated	O
With	O
Long-term	O
Bisphosphonate	O
and	O
Denosumab	B:C1690432
.	O

Atypical	B:C4268744
femoral	I:C4268744
fractures	I:C4268744
(	O
Atypical	O
femoral	I:C4268744
fractures	I:C4268744
)	O
occur	O
in	O
osteoporosis	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
.	O

Atypical	O
femoral	I:C4268744
fractures	I:C4268744
(	O
Atypical	B:C4268744
femoral	I:C4268744
fractures	I:C4268744
)	O
occur	O
in	O
osteoporosis	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
.	O

Atypical	O
femoral	I:C4268744
fractures	I:C4268744
(	O
Atypical	O
femoral	I:C4268744
fractures	I:C4268744
)	O
occur	O
in	O
osteoporosis	B:C0029456
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
.	O

Atypical	O
femoral	I:C4268744
fractures	I:C4268744
(	O
Atypical	O
femoral	I:C4268744
fractures	I:C4268744
)	O
occur	O
in	O
osteoporosis	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	B:C2267018
.	O

Atypical	B:C4268744
femoral	I:C4268744
fractures	I:C4268744
also	O
occur	O
in	O
cancer	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
but	O
the	O
prevalence	O
is	O
low	O
.	O

Atypical	O
femoral	I:C4268744
fractures	I:C4268744
also	O
occur	O
in	O
cancer	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	B:C2267018
or	O
denosumab	O
,	O
but	O
the	O
prevalence	O
is	O
low	O
.	O

Atypical	O
femoral	I:C4268744
fractures	I:C4268744
also	O
occur	O
in	O
cancer	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	B:C1690432
,	O
but	O
the	O
prevalence	O
is	O
low	O
.	O

We	O
describe	O
a	O
53	O
-	O
year	O
-	O
old	O
woman	B:C0043210
with	O
a	O
history	O
of	O
medullary	O
thyroid	I:C0238462
cancer	I:C0238462
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	O
for	O
6	O
years	O
and	O
denosumab	O
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

We	O
describe	O
a	O
53	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
medullary	B:C0238462
thyroid	I:C0238462
cancer	I:C0238462
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	O
for	O
6	O
years	O
and	O
denosumab	O
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

We	O
describe	O
a	O
53	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
medullary	O
thyroid	I:C0238462
cancer	I:C0238462
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	B:C2267018
for	O
6	O
years	O
and	O
denosumab	O
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

We	O
describe	O
a	O
53	O
-	O
year	O
-	O
old	O
woman	O
with	O
a	O
history	O
of	O
medullary	O
thyroid	I:C0238462
cancer	I:C0238462
and	O
skull	O
metastasis	O
who	O
was	O
prescribed	O
bisphosphonate	O
for	O
6	O
years	O
and	O
denosumab	B:C1690432
for	O
1.5	O
years	O
,	O
consecutively	O
.	O

Bone	B:C3889015
scintigraphy	I:C3889015
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	I:C0239783
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	I:C0817320
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

Bone	O
scintigraphy	I:C3889015
performed	O
because	O
of	O
spontaneous	O
groin	B:C0239783
pain	I:C0239783
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	I:C0817320
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

Bone	O
scintigraphy	I:C3889015
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	I:C0239783
showed	O
uptake	B:C0243144
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	I:C0817320
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

Bone	O
scintigraphy	I:C3889015
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	I:C0239783
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	B:C0817320
femur	I:C0817320
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	O
.	O

Bone	O
scintigraphy	I:C3889015
performed	O
because	O
of	O
spontaneous	O
groin	O
pain	I:C0239783
showed	O
uptake	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
femur	I:C0817320
,	O
which	O
was	O
confirmed	O
as	O
impending	O
AFF	B:C4268744
.	O

In	O
oncological	B:C0027651
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	B:C2267018
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	B:C1690432
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	B:C4268744
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	B:C0011906
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	B:C0205234
femoral	O
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	B:C0015811
findings	O
.	O

In	O
oncological	O
patients	O
receiving	O
long	O
-	O
term	O
bisphosphonate	O
or	O
denosumab	O
,	O
AFF	O
should	O
be	O
included	O
as	O
a	O
differential	O
diagnosis	I:C0011906
with	O
focal	O
femoral	O
findings	B:C0243095
.	O

